• Secured three U.S. commercial customers, converting foundation partners
• Achieved first fee-per-scan revenues from FDA-cleared Salix® Coronary Plaque module
• Expanded SAPPHIRE Study with major U.S. hospital systems as participants

Artrya Limited (ASX: AYA) reported its quarterly activities and cash flow for the period ended 31 December 2025. Key highlights include:- Commercial foundations laid for 2026 growth, with three U.S. foundation partners now converted to commercial customers, including Cone Health and Northeast Georgia Health System.- Major milestone achieved with first fee-per-scan revenues from use of the FDA-cleared Salix® Coronary Plaque module at Tanner Health, Artrya's first U.S. commercial customer.- Established a U.S.-based Customer Success Team to support customer engagement, integration and rollout.- Significant progress with the SAPPHIRE Study, with all major U.S. hospital systems confirmed as participants ahead of the study launch in early 2026.- Completed a Q-Submission meeting with the FDA, providing clear guidance for the regulatory pathway of the Salix® Coronary Flow module, targeting 510(k) clearance by 30 June 2026.- Included in the S&P/ASX All Technology Index, further elevating Artrya's market visibility.- Maintained a strong cash position of $76.5 million at 31 December 2025, with an additional $5.6 million R&D tax rebate expected in Q1 2026.

Artrya expects to achieve 510(k) clearance for the Salix® Coronary Flow module by 30 June 2026, which will enable the commercial launch of this product in the second half of 2026.

Artrya is focused on expanding the clinical use of its Salix® platform, including the Salix® Coronary Flow module, and scaling its commercial operations with its growing customer base in 2026.